Invesco
VERV

Invesco’s Verve Therapeutics VERV Stock Holding History

Invesco’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-143,445
Closed -$1.61M – 3861
2025
Q2 		$1.61M Buy
143,445
+58,085
+68% +$331K ﹤0.01% 2653
2025
Q1 		$390K Buy
85,360
+28,220
+49% +$189K ﹤0.01% 3252
2024
Q4 		$322K Buy
57,140
+3,080
+6% +$17.4K ﹤0.01% 3392
2024
Q3 		$262K Sell
54,060
-971
-2% -$5.64K ﹤0.01% 3452
2024
Q2 		$269K Sell
55,031
-2,131
-4% -$13.4K ﹤0.01% 3537
2024
Q1 		$759K Buy
57,162
+31,144
+120% +$413K ﹤0.01% 3124
2023
Q4 		$363K Buy
26,018
+5,860
+29% +$72.6K ﹤0.01% 3373
2023
Q3 		$267K Sell
20,158
-101
-0.5% -$1.63K ﹤0.01% 3500
2023
Q2 		$380K Sell
20,259
-1,822
-8% -$30.3K ﹤0.01% 3394
2023
Q1 		$318K Buy
22,081
+5,823
+36% +$114K ﹤0.01% 3477
2022
Q4 		$315K Sell
16,258
-148,918
-90% -$3.95M ﹤0.01% 3490
2022
Q3 		$5.67M Buy
165,176
+152,057
+1,159% +$4.85M ﹤0.01% 2157
2022
Q2 		$201K Buy
13,119
+3,220
+33% +$49.9K ﹤0.01% 3726
2022
Q1 		$226K Buy
9,899
+2,606
+36% +$74.5K ﹤0.01% 3748
2021
Q4 		$269K Buy
7,293
+2,024
+38% +$85K ﹤0.01% 3660
2021
Q3 		$248K Buy
+5,269
New +$310K ﹤0.01% 3719

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Invesco's VERV Position: Q3 2025 in Review

Invesco sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 143,445 shares — an estimated $1.61M sold.

Invesco first reported a position in VERV in Q3 2021 and held it in 16 quarters. The position peaked at $5.67M in Q3 2022. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Invesco reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Invesco sold 143,445 Verve Therapeutics shares in Q3 2025, an estimated $1.61M.
  • Invesco first reported a position in Verve Therapeutics in Q3 2021 and held it in 16 quarters.
  • Invesco's Verve Therapeutics position peaked at $5.67M in Q3 2022.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Invesco's 13F filing for Q3 2025, filed 13 Nov 2025.